GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Kintara Therapeutics
KWESST develops tactical systems for military and law enforcement agencies. Its share price reflects the bet that its innovative products will be adopted into military service. The chart reflects the company's dependence on winning defense contracts.
Share prices of companies in the market segment - General oncology therapy
Kintara Therapeutics is a biopharmaceutical company developing treatments for oncology diseases with high unmet needs. We have classified the company in the "General Oncology" category. The chart below shows how investors value companies in late-stage clinical trials.
Broad Market Index - GURU.Markets
Kintara Therapeutics is an oncology company developing drugs to treat cancer. As a participant in this sector, it is included in our GURU.Markets index. The chart below reflects the overall stock market performance. Compare it with the company's stock price to assess the outlook for this industry.
Change in the price of a company, segment, and market as a whole per day
KTRA - Daily change in the company's share price Kintara Therapeutics
Kintara Therapeutics' daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its brain cancer drugs.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Kintara Therapeutics develops drugs to treat cancer, particularly brain cancer. This is one of the most complex and risky areas in oncology. The chart below illustrates the high volatility typical of this segment, reflecting the enormous risks and potential breakthroughs.
Daily change in the price of a broad market stock, index - GURU.Markets
Kintara Therapeutics is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Kintara Therapeutics
For Kintara Therapeutics, year-over-year performance tells the story of its struggle to develop cancer drugs. Its market cap change over the past 12 months reflects its difficult journey, including clinical trial setbacks. Its valuation reflects investors' faith in the company's ability to find a new path or make a deal to survive.
Annual dynamics of market capitalization of the market segment - General oncology therapy
As an early-stage biotech company, Kintara is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kintara Therapeutics, an oncology company developing drugs to treat brain cancer, is tackling one of the most complex challenges in medicine. Its year-over-year market capitalization represents a high-risk bet on scientific success. Positive data could trigger a sharp rise, while failure could send the stock plummeting.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Kintara Therapeutics
Kintara is a clinical-stage oncology company focused on brain tumors. Its monthly performance is entirely dependent on the results of its clinical trials. The results of its lead drug are a binary outcome event for its stock.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
This chart reflects the dynamics of the volatile biotech sector. For Kintara, a clinical-stage oncology company, it's the backdrop. Its movements demonstrate how successes and, especially, failures in clinical trials can dramatically impact the valuation of such companies.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kintara Therapeutics is a biotech company developing cancer treatments. Following clinical failures, the company is exploring new strategic options. The overall market chart is irrelevant; Kintara shares are driven by news about the company's survival and potential deals, not by overall trends, and are highly speculative.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Kintara Therapeutics
Kintara Therapeutics is a late-stage oncology company developing drugs for the treatment of brain cancer. Its weekly stock price is highly sensitive to news about clinical trials and regulatory decisions.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Kintara Therapeutics is focused on developing drugs to treat cancer, particularly brain tumors. This is one of the most complex areas in oncology. The chart below will help determine whether the company's stock price fluctuations are a reaction to its own clinical data or reflect the overall hopes and disappointments in this field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Kintara is a biotech company whose stock moves on news about clinical trials. This chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
KTRA - Market capitalization of the company Kintara Therapeutics
The market capitalization of Kintara Therapeutics, a late-stage oncology company, reflects the high risks of biotech development. Its low valuation and volatility reflect investor doubts about the success of its lead drug candidates in late-stage clinical trials.
KTRA - Share of the company's market capitalization Kintara Therapeutics within the market segment - General oncology therapy
Kintara Therapeutics is a small biotech company focused on oncology. Its market share in the pharmaceutical sector is negligible. Its market capitalization is highly volatile and serves as a barometer of investor sentiment, reacting to any news about the progress of its experimental drugs' clinical trials.
Market capitalization of the market segment - General oncology therapy
Here's a chart showing the biotech sector's market capitalization. Kintara Therapeutics is a company developing drugs to treat difficult-to-treat cancers, particularly brain cancer. Its market history exemplifies the difficulty of treating the most aggressive tumors and the high risks associated with this area of oncology.
Market capitalization of all companies included in a broad market index - GURU.Markets
Kintara is an oncology company developing drugs to treat brain cancer. Its market capitalization reflects the hope of developing an effective therapy for this deadly disease. The chart below shows the economic weight of companies working in this important field.
Book value capitalization of the company, segment and market as a whole
KTRA - Book value capitalization of the company Kintara Therapeutics
Kintara's book value is derived from its equity and the intellectual property in its two oncology drug candidates. The chart tells the story of a biotech company that, after clinical trial failures, uses its remaining resources to explore strategic alternatives or continue research in niche markets.
KTRA - Share of the company's book capitalization Kintara Therapeutics within the market segment - General oncology therapy
Kintara Therapeutics develops drugs to treat brain cancer. The chart shows its share of actual R&D assets. These are its clinical programs, which provide the foundation for testing and commercializing new therapies.
Market segment balance sheet capitalization - General oncology therapy
Kintara Therapeutics is a biopharmaceutical company focused on oncology. Their asset-light model focuses on development and clinical trials rather than plant construction. A book value chart shows their modest financial base, as their primary asset is science.
Book value of all companies included in the broad market index - GURU.Markets
Kintara Therapeutics' assets include laboratories and R&D centers developing therapies for brain cancer and other oncological diseases. The chart shows how the company built its scientific and material capital to advance its research.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Kintara Therapeutics
Kintara Therapeutics is a biotech company focused on cancer treatment. Its book value is primarily derived from cash flow from research. The chart below visualizes the risks and hopes. The company's performance will be determined entirely by clinical trial results.
Market to book capitalization ratio in a market segment - General oncology therapy
Kintara Therapeutics is a biotech company developing drugs to treat difficult-to-treat cancers such as glioblastoma (brain cancer). Its valuation depends on the success of its clinical programs. The chart shows how its market capitalization, based on expectations, compares to its current assets.
Market to book capitalization ratio for the market as a whole
Kintara Therapeutics is a company developing drugs for the treatment of difficult-to-treat cancers. Its valuation is entirely dependent on the results of clinical trials. This metric demonstrates that the market value is a bet on the future success of its drugs, not a valuation of its current tangible assets.
Debts of the company, segment and market as a whole
KTRA - Company debts Kintara Therapeutics
Kintara Therapeutics is a biotech company that has experienced setbacks in clinical trials of its oncology drugs. This graph reflects its financial difficulties. The company was forced to halt key research and is now exploring strategic alternatives, including a merger or asset sale.
Market segment debts - General oncology therapy
Kintara Therapeutics is another biotech company focused on oncology. After a series of clinical trial failures, the company is exploring new avenues for development. This chart may reflect the company's financial health during a period of crisis, when it is attempting to restructure its strategy or find new assets.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Kintara Therapeutics
Kintara Therapeutics is another clinical-stage oncology company. This chart shows its financial structure. For a company whose developments have not yet been approved, debt is a significant burden, increasing financial risks in the event of delays or failures in trials.
Market segment debt to market segment book capitalization - General oncology therapy
Kintara Therapeutics is a biopharmaceutical company developing drugs to treat oncology. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to fund its clinical research and development efforts to develop new cancer treatments.
Debt to book value of all companies in the market
Kintara Therapeutics is a biopharmaceutical company developing drugs to treat difficult-to-treat cancers such as glioblastoma. This is a high-risk area with a significant unmet need. This chart of total market debt demonstrates how favorable the investment climate is overall for such risky biotech projects.
P/E of the company, segment and market as a whole
P/E - Kintara Therapeutics
Kintara Therapeutics was a biotech company developing drugs to treat oncology, particularly brain cancer. This chart reflects clinical trial failures and the subsequent search for strategic alternatives.
P/E of the market segment - General oncology therapy
Kintara Therapeutics is a biopharmaceutical company developing cancer treatments. Its pipeline includes candidates for glioblastoma (brain cancer) and other difficult-to-treat tumors. This chart shows the average valuation for the oncology therapeutics sector, reflecting how investors assess the risks and potential of smaller biotech companies.
P/E of the market as a whole
Kintara Therapeutics is a biopharmaceutical company developing drugs for the treatment of oncology diseases. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant for the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Kintara Therapeutics
Kintara Therapeutics is a biopharmaceutical company developing drugs to treat oncology conditions with high unmet needs. This chart shows market expectations for the success of its clinical programs. Future revenue is entirely dependent on regulatory approvals and the commercial potential of its drugs.
%20P%2FE%20Kintara%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kintara-Therapeutics&v=1772513830739 "Chart of the company's future (projected) P/E Kintara Therapeutics")
Future (projected) P/E of the market segment - General oncology therapy
Kintara Therapeutics is a biopharmaceutical company developing drugs to treat oncology diseases with high unmet needs. The chart reflects average expectations for the oncology segment. KTRA's position relative to this benchmark reflects investors' assessment of their clinical pipeline and the likelihood of successfully bringing new cancer treatments to market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772513830749 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Kintara Therapeutics is a biopharmaceutical company developing drugs to treat cancers with high unmet needs. The company is focused on two main programs: glioblastoma and cutaneous T-cell lymphoma. This chart of overall market expectations is a barometer of investor appetite for funding risky but potentially breakthrough oncology projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513830793 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Kintara Therapeutics
Kintara Therapeutics is a biotech company developing drugs to treat difficult-to-treat cancers such as glioblastoma. Its financial schedule is driven by clinical trial expenses. Potential profitability depends on the success of its candidates in combating these aggressive tumors.
Profit of companies in the market segment - General oncology therapy
Kintara Therapeutics is a biopharmaceutical company developing cancer treatments, with leading candidates for glioblastoma and cutaneous metastasis of breast cancer. This chart shows the overall profitability of the oncology sector. It reflects the willingness of investors to fund breakthrough but risky developments and the overall progress of the sector in the fight against cancer.
Overall market profit
Kintara Therapeutics is a biopharmaceutical company focused on developing drugs for the treatment of difficult-to-treat cancers, such as glioblastoma. Its future depends on the success of clinical trials. The positive economic backdrop, visible in this chart, is important for attracting the investment needed to advance its drug candidates.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Kintara Therapeutics
Kintara Therapeutics is a biopharmaceutical company developing drugs to treat cancer, particularly glioblastoma, an aggressive form of brain cancer. This chart reflects analysts' expectations for the commercial potential of its candidates, which is associated with the very high risks of clinical trials in oncology.
%20profit%20of%20the%20company%20Kintara%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kintara-Therapeutics&v=1772513830827 "Graph of future (projected) profit of the company Kintara Therapeutics")
Future (predicted) profit of companies in the market segment - General oncology therapy
Kintara Therapeutics is a biotech company focused on developing drugs to treat difficult-to-treat cancers, such as glioblastoma. The company's success depends on clinical trial results in complex areas of oncology. This chart reflects forecasts for the entire biotech sector, helping to assess Kintara's potential and risks in the fight against the most aggressive tumors.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772513830840 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Kintara Therapeutics is a biopharmaceutical company focused on cancer treatments. Like other clinical-stage companies in this sector, its prospects depend on research success rather than macroeconomic indicators. This earnings curve is largely irrelevant for assessing its potential.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513830843 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Kintara Therapeutics
Kintara Therapeutics is a biopharmaceutical company developing drugs to treat difficult-to-treat cancers. Its valuation, shown on this chart, reflects investor expectations for the success of its clinical programs. Its price action reflects news about trials and regulatory decisions.
P/S market segment - General oncology therapy
Kintara Therapeutics is a biopharmaceutical company developing treatments for oncology. Future revenue depends on the success of its clinical programs. This chart for the oncology sector compares investor expectations for Kintara's pipeline with those of other companies in the field.
P/S of the market as a whole
Kintara Therapeutics is a biopharmaceutical company developing treatments for oncological diseases with high unmet needs, particularly brain cancer. This market revenue valuation chart helps understand how investors assess the risks and potential of this company operating in one of the most complex areas of oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Kintara Therapeutics
Kintara Therapeutics is a biopharmaceutical company developing drugs to treat oncology diseases with high unmet needs, particularly brain cancer. This chart shows how the market assesses the future commercial potential of its lead candidates. It reflects investor expectations for success in complex clinical trials.
%20P%2FS%20Kintara%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kintara-Therapeutics&v=1772513830872 "The graph of the company's future (projected) P/S Kintara Therapeutics")
Future (projected) P/S of the market segment - General oncology therapy
Kintara Therapeutics is a biotech company developing drugs to treat oncology conditions with high unmet needs. The company's valuation reflects investors' opinions on the potential of its lead candidates in late-stage clinical trials, making it sensitive to news about trial results.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772513830887 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Kintara Therapeutics is a biopharmaceutical company developing drugs for the treatment of oncological diseases, particularly brain cancer. Its success depends on the results of clinical trials. In the overall revenue growth picture illustrated by the chart, Kintara represents the innovative sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513830910 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Kintara Therapeutics
Kintara Therapeutics is a clinical-stage biotechnology company developing cancer treatments. The company currently has no commercial products and, therefore, no sales revenue. Any revenue reflected in the chart is from partner funding or licensing.
Sales of companies in the market segment - General oncology therapy
Kintara Therapeutics (KTRA) is a biopharmaceutical company developing cancer treatments. Its lead candidates target glioblastoma and other oncological diseases. This metric reflects revenue in the oncology sector. Kintara strives to offer new options for patients with diseases for which there is a critical shortage of effective treatments.
Overall market sales
Kintara Therapeutics is a biotech company developing drugs to treat difficult-to-treat cancers. Its future depends on the results of clinical trials. This overall economic activity pattern affects the availability of funding for small biotech companies. Growing markets allow them to raise funds to continue their research programs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Kintara Therapeutics
Kintara Therapeutics is a biotech company developing drugs to treat difficult-to-treat cancers such as glioblastoma. Its future revenue is entirely dependent on the results of clinical trials and the commercialization of its candidates. This chart reflects analyst expectations, which are essentially an assessment of the scientific potential and commercial prospects of its developments.
%20sales%20of%20the%20company%20Kintara%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kintara-Therapeutics&v=1772513830966 "Schedule of future (projected) sales of the company Kintara Therapeutics")
Future (projected) sales of companies in the market segment - General oncology therapy
Kintara Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments. This forecast chart reflects the potential future revenue from their pipeline of candidates. It represents analysts' views on the commercial prospects of their approaches to treating difficult-to-treat tumors.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772513830994 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Kintara Therapeutics is a biopharmaceutical company developing drugs to treat complex forms of cancer, such as glioblastoma. Its future depends on the results of clinical trials. This chart shows overall market sentiment, but for Kintara, demonstrating that its therapy can prolong the lives of patients with the most deadly cancers is key.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513830997 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Kintara Therapeutics
Kintara Therapeutics is a biopharmaceutical company developing drugs to treat difficult-to-treat cancers such as glioblastoma. While in clinical trials, it incurs significant expenses. The chart shows the financial trajectory of a company focused on solving some of the most complex problems in oncology.
Market segment marginality - General oncology therapy
Kintara Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer treatments, specifically glioblastoma. This chart reflects its operating expenses. The path to profitability lies through successful clinical trials and regulatory approval of its drugs.
Market marginality as a whole
Kintara Therapeutics is a biotech company developing drugs to treat oncology. Like many companies in this sector, it relies on clinical trial results and funding. This total return chart reflects investor risk appetite, which is typically higher during periods of economic growth and high corporate profitability.
Employees in the company, segment and market as a whole
Number of employees in the company Kintara Therapeutics
Kintara Therapeutics is a small biotech company focused on developing treatments for difficult-to-treat cancers such as glioblastoma (brain cancer). This graph shows the compact team advancing its core technologies through complex clinical trials in hopes of helping patients with limited treatment options.
Share of the company's employees Kintara Therapeutics within the market segment - General oncology therapy
Kintara Therapeutics is a biopharmaceutical company in late-stage clinical development focused on cancer treatment. As the company approaches commercialization, its workforce is expected to grow. This chart reflects its current stage of development and investments in human capital to complete key clinical trials.
Number of employees in the market segment - General oncology therapy
Kintara Therapeutics focuses on cancer treatment, particularly brain tumors. This chart, reflecting oncology therapy activity, highlights the complexity and urgent need for new treatments for diseases like glioblastoma. For Kintara, the growing number of researchers in this field represents both scientific advancement and intense competition.
Number of employees in the market as a whole
Kintara Therapeutics is a biotech company focused on developing treatments for oncology diseases with high unmet needs. Its success depends on clinical trial results and access to capital. The overall economic health reflected in this occupancy rate influences investor willingness to fund risky but socially significant projects.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Kintara Therapeutics (KTRA)
Kintara Therapeutics (KTRA) is a biotech company developing oncology drugs. As with any biotech company in the R&D stage, this chart shows the market valuation of their scientific platform. Their market capitalization is not dependent on their headcount, but is determined solely by the potential of their developments and the value of their intellectual property.
%20of%20the%20company%20Kintara%20Therapeutics%20(KTRA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kintara-Therapeutics-KTRA&v=1772513831053 "Chart of market capitalization per employee (in thousands of dollars) of the company Kintara Therapeutics (KTRA)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Kintara Therapeutics is a biopharmaceutical company developing cancer treatments. Its market capitalization is based on the potential of its clinical pipeline. This metric demonstrates the future value the market places on the work of each scientist who can advance the development of a new drug.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772513831083 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Kintara Therapeutics is a late-stage biopharmaceutical company focused on treating brain cancer. Its valuation depends on the results of its final clinical trials. This chart for Kintara illustrates how, in biotech, market capitalization per employee reflects the likelihood of success and the potential market size of its drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513831091 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Kintara Therapeutics (KTRA)
Kintara Therapeutics is another biotech R&D company focused on oncology. Like its peers in the sector, it is unprofitable. This chart shows expenses, not revenue: the loss (investment) per employee working on clinical trials and drug development.
%20Chart%20Kintara%20Therapeutics%20(KTRA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kintara-Therapeutics-KTRA&v=1772513831118 "Company Profit Per Employee (in thousands of dollars) Chart Kintara Therapeutics (KTRA)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Kintara Therapeutics is a biopharmaceutical company developing cancer treatments, particularly for brain tumors. Success in this complex field hinges on the effectiveness of clinical trials. This graph shows the value each employee creates while working to solve one of the most challenging problems in oncology, which is crucial for assessing the company's potential.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772513831125 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Kintara Therapeutics is a biotech company developing drugs to treat cancer, particularly brain tumors (glioblastoma). This is pure R&D. This chart, showing the market average profit per employee, provides important context. It illustrates how high the stakes are in biotech, where a single successful development can generate colossal profits per scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513831148 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Kintara Therapeutics (KTRA)
Kintara Therapeutics is a biopharmaceutical company developing drugs for the treatment of oncology. Being in clinical trials, the company has no commercial revenue yet. The chart shows zero revenue, and its future growth depends on the successful completion of trials and approval of its drug candidates.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kintara-Therapeutics-KTRA&v=1772513831173 "Sales chart per company employee Kintara Therapeutics (KTRA)")
Sales per employee in the market segment - General oncology therapy
Kintara Therapeutics (KTRA) is a biopharmaceutical company developing drugs to treat cancer, specifically glioblastoma (brain cancer). This chart shows the average revenue per employee in the sector. It is important for assessing the company's capital and personnel efficiency during clinical trials compared to its competitors.
Sales per employee for the market as a whole
Kintara Therapeutics (KTRA) is a biotech company developing treatments for cancer, particularly brain tumors (glioblastomas). The company is in the clinical stage. This near-zero figure reflects ongoing investment in research staff working on drugs for some of the most challenging cancer types.
Short shares by company, segment and market as a whole
Shares shorted by company Kintara Therapeutics (KTRA)
Kintara Therapeutics (KTRA) is a microcap biotech that has suffered a series of clinical failures. This chart shows short interest. The high bearish bets reflect investor bets that the company has no valuable assets left and is headed for delisting or liquidation due to constant cash burn. (341)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kintara-Therapeutics-KTRA&v=1772513831231 "Short Shares Chart for the Company Kintara Therapeutics (KTRA)")
Shares shorted by market segment - General oncology therapy
Kintara Therapeutics (KTRA) is a biotech company developing drugs to treat oncology, particularly brain cancer. The chart below shows a general short position in the biotech sector. It demonstrates investors' general skepticism about the success of risky clinical trials.
Shares shorted by the overall market
Kintara (KTRA) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing KTRA will be unable to raise funds to continue R&D.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Kintara Therapeutics (KTRA)
This oscillator for Kintara is a story of struggle in biotech. The company is focused on treating brain cancer but has suffered setbacks in key trials. "Overheating" (above 70) can only be caused by M&A rumors. Research failures (as with REM-001) and a persistent cash shortage keep the stock deeply "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kintara-Therapeutics-KTRA&v=1772513831269 "RSI 14 indicator chart for the company's stock Kintara Therapeutics (KTRA)")
RSI 14 Market Segment - General oncology therapy
Kintara (KTRA) is a clinical-stage biotech whose fate hinges on the success of its oncology developments. It's an all-or-nothing bet. This chart measures the overall sentiment in the Oncology sector. It helps distinguish Kintara's successful trials from overall "overheated" or "oversold" sentiment across the biotech sector.
RSI 14 for the overall market
For Kintara Therapeutics, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KTRA (Kintara Therapeutics)
Kintara Therapeutics is a biotech company focused on developing drugs to treat cancer (including brain cancer and glioblastoma). This chart shows the speculative average 12-month price target from analysts, which is based almost entirely on their assessment of clinical trial data and the company's future R&D pipeline.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KTRA-Kintara-Therapeutics&v=1772513831282 "A chart showing analyst consensus forecasts for the expected stock price. KTRA (Kintara Therapeutics)")
The difference between the consensus estimate and the actual stock price KTRA (Kintara Therapeutics)
Kintara (KTRA) is a biotech company developing drugs to treat brain cancer (glioblastoma) and other difficult-to-treat tumors. This chart measures the gap between the current share price and the consensus target price. It shows how confident experts are in their R&D portfolio and their chances of success in this challenging area of oncology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KTRA-Kintara-Therapeutics&v=1772513831287 "A chart showing the difference between the consensus forecast and the actual stock price. KTRA (Kintara Therapeutics)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Kintara Therapeutics (KTRA) is a biotech company focused on one of the deadliest forms of cancer: glioblastoma (brain cancer). This chart reflects the collective analyst consensus on the *entire* oncology R&D sector. It shows whether experts believe a breakthrough can be achieved in this notorious R&D drug "graveyard."
Analysts' consensus forecast for the overall market share price
Kintara Therapeutics is a biotech company focused on cancer treatment, including brain cancer. This is a high-risk area. This chart reflects the overall market "risk appetite." For KTRA, whose price represents a breakout option, overall market optimism (a rising chart) is critical to funding multi-year trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Kintara Therapeutics
Kintara is a biotech R&D company that has lost its way. Their flagship R&D (for brain cancer - GBM) failed in clinical trials. This chart is a summary indicator of their battle for survival. It reflects not their R&D prospects, but the (nearly zero) value of their technologies and their (desperate) fight to avoid delisting.
AKIMA Market Segment Index - General oncology therapy
Kintara Therapeutics is an oncology biotech. They are working on two platforms: one for the treatment of brain cancer (glioblastoma), and the other for delivering chemotherapy directly to the tumor. This is a general oncology therapeutic. This chart compares their composite index to the sector, showing how their R&D strategy compares to others.
The AKIM Index for the overall market
Kintara Therapeutics is a biopharmaceutical company developing treatments for rare cancers. It is merging with TuHURA Biosciences. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, as it undergoes transformation, compares to overall economic trends.
